SCHEMBL680676

SCHEMBL680676

CC(=O)NCC1CCC(C(=O)O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.50
PLAT P00750 1/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 3/20 0.45
CYP2C9 P11712 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MMP12 P39900 1/20 0.41
EPHX1 P07099 1/20 0.41
ANPEP P15144 1/20 0.41
ENPEP Q07075 1/20 0.41
VCP P55072 3/20 0.40
CACNA1H O95180 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680677 1.00 PLG (0.50) PLGPLATLMNAKMT2ATDP1
Tranexamic Acid SCHEMBL2569232 0.91 PLG (0.67) PLGPLATLMNAKMT2ATDP1
SCHEMBL2340454 0.89 PLG (0.42) PLGPLATLMNAKMT2ATDP1
SCHEMBL22571032 0.89 PLG (0.42) PLGPLATLMNAKMT2ATDP1
SCHEMBL2340458 0.89 PLG (0.42) PLGPLATLMNAKMT2ATDP1
SCHEMBL2340457 0.89 PLG (0.42) PLGPLATLMNAKMT2ATDP1
SCHEMBL13165688 0.87 TDP1 (0.58) TDP1ALDH1A1SMN1; SMN2EPHX1CACNA1H
SCHEMBL48633 0.87
SCHEMBL22721999 0.86 TDP1 (0.48) KMT2ATDP1ALDH1A1MEN1SMN1; SMN2
SCHEMBL12513444 0.86 TDP1 (0.48) KMT2ATDP1ALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229086-A1 ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF SKINOSIVE (FR) 2025-11-06 WO claimed
CN-103172528-B Tranexamic acid preparation method :YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) 2014-10-08 CN claimed
JP-7233041-A None JP disclosed
JP-7233090-A None JP disclosed
WO-2025229086-A1 ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF SKINOSIVE (FR) 2025-11-06 WO disclosed
WO-2024080290-A1 MELANIN PIGMENT SYNTHESIS INHIBITOR 一丸ファルコス株式会社 2024-04-18 WO disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
CN-113631144-A Cosmetic containing ultraviolet wavelength conversion substance and medicinal agent 株式会社资生堂 2021-11-09 CN disclosed
WO-2021064189-A2 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2021-04-08 WO disclosed
WO-2020204191-A1 COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH CONVERSION SUBSTANCE AND MEDICINAL AGENT 株式会社 資生堂 2020-10-08 WO disclosed
CN-102300839-B Method For Manufacturing Trans-{4-[(alkyl Amino) Methyl] Cyclohexyl} Acetic Ester KOWA CO 2014-12-10 CN disclosed
EP-1466625-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed
EP-0585130-B1 External preparation for skin containing a depigmentation agent SHISEIDO CO LTD (JP) 1998-01-28 EP disclosed
US-5690914-A TRANEXAMIC ACID DERIVATIVES FOR DEPIGMENTATION SHISEIDO CO., LTD (JP) 1997-11-25 US disclosed
JP-H07233090-A EXTERNAL AGENT FOR SKIN SHISEIDO CO LTD 1995-09-05 JP disclosed
JP-H07233041-A SKIN EXTERNAL PREPARATION SHISEIDO CO LTD 1995-09-05 JP disclosed
EP-0585130-A2 External preparation for skin containing a depigmentation agent SHISEIDO COMPANY LIMITED (JP) 1994-03-02 EP disclosed
US-4267174-A AND PROCESS FOR ADMINISTERING BOEHRINGER MANNHEIM, GMBH (DE) 1981-05-12 US disclosed
US-4081541-A Steroid derivatives RORER ITALIANA S.P.A. (IT) 1978-03-28 US disclosed
US-4011317-A STEROID DERIVATIVES RORER ITALIANA S.P.A. (IT) 1977-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT PLG 917/4885PLAT 1281/4885LMNA 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.